- Home
- VALN vs LAB Comparison
VALN vs LAB Comparison
Compare VALN & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- LAB
- Stock Information
- Founded
- VALN 2012
- LAB 1999
- Country
- VALN France
- LAB United States
- Employees
- VALN N/A
- LAB N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- VALN Health Care
- LAB Industrials
- Exchange
- VALN Nasdaq
- LAB Nasdaq
- Market Cap
- VALN 510.7M
- LAB 451.0M
- IPO Year
- VALN 2021
- LAB 2011
- Fundamental
- Price
- VALN $6.40
- LAB $1.01
- Analyst Decision
- VALN Strong Buy
- LAB Buy
- Analyst Count
- VALN 3
- LAB 2
- Target Price
- VALN $15.33
- LAB $2.50
- AVG Volume (30 Days)
- VALN 83.3K
- LAB 1.6M
- Earning Date
- VALN 05-07-2025
- LAB 05-06-2025
- Dividend Yield
- VALN N/A
- LAB N/A
- EPS Growth
- VALN N/A
- LAB N/A
- EPS
- VALN N/A
- LAB N/A
- Revenue
- VALN $201,099,222.00
- LAB $169,687,000.00
- Revenue This Year
- VALN $18.74
- LAB N/A
- Revenue Next Year
- VALN $29.26
- LAB $12.18
- P/E Ratio
- VALN N/A
- LAB N/A
- Revenue Growth
- VALN 21.64
- LAB 33.86
- 52 Week Low
- VALN $3.62
- LAB $0.92
- 52 Week High
- VALN $9.50
- LAB $2.65
- Technical
- Relative Strength Index (RSI)
- VALN 48.49
- LAB 44.66
- Support Level
- VALN $6.18
- LAB $1.00
- Resistance Level
- VALN $6.54
- LAB $1.09
- Average True Range (ATR)
- VALN 0.21
- LAB 0.08
- MACD
- VALN 0.01
- LAB -0.00
- Stochastic Oscillator
- VALN 54.35
- LAB 33.33
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.